Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.
-------- Â
58:18
--------
58:18
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
-------- Â
17:44
--------
17:44
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here.
-------- Â
59:02
--------
59:02
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here.
-------- Â
1:28:41
--------
1:28:41
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress
Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
Ireland